Pacer Advisors
SLNO

Pacer Advisors’s Soleno Therapeutics SLNO Stock Holding History

Pacer Advisors’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-307
Closed -$12.5K – 2682
2024
Q2 		$12.5K Sell
307
-184
-37% -$7.8K ﹤0.01% 3514
2024
Q1 		$21K Buy
+491
New +$22.2K ﹤0.01% 3434

Other funds holding SLNO

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Pacer Advisors's SLNO Position: Q3 2024 in Review

Pacer Advisors sold out of Soleno Therapeutics (SLNO) in Q3 2024, closing a stake of 307 shares — an estimated $12.5K sold.

Pacer Advisors first reported a position in SLNO in Q1 2024 and held it in 2 quarters. The position peaked at $21K in Q1 2024. 142 funds tracked by Wall St. Rank hold SLNO as of Q3 2024.

  • Pacer Advisors reported no remaining Soleno Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 307 Soleno Therapeutics shares in Q3 2024, an estimated $12.5K.
  • Pacer Advisors first reported a position in Soleno Therapeutics in Q1 2024 and held it in 2 quarters.
  • Pacer Advisors's Soleno Therapeutics position peaked at $21K in Q1 2024.
  • 142 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.